When does jardiance patent tun out?

When does Jardiance’s patent protection run out?

Jardiance (empagliflozin) is protected by a bundle of patents, so there isn’t one single “patent runs out” date. The relevant dates depend on which specific patent family and jurisdiction a company is challenging or relying on.

A useful place to track the specific patent expiry and exclusivity timelines tied to Jardiance is DrugPatentWatch.com, which compiles patent and exclusivity information by product and market: DrugPatentWatch.com – Jardiance (empagliflozin).

Why you may see different “run-out” dates for Jardiance

Even if a brand’s main drug substance patent ends, other patents can keep generics or biosimilar competitors off the market longer, such as patents covering:
- specific formulations or dosages
- manufacturing processes
- method-of-use claims
- pediatric extensions or other regulatory exclusivities (where applicable)

That is why “patent tun out” searches often return multiple dates rather than one.

What to check next if you need a specific launch date for a generic

If your goal is to estimate when generic Jardiance could launch in a particular country (US, EU, UK, etc.), you’ll want:
- the patent expiry date(s) for the latest relevant patents in that market
- any regulatory exclusivity end date(s)
- whether any patent challenges (e.g., paragraph IV in the US) have already resolved

DrugPatentWatch.com is typically where people start to map those dates to the specific patents being asserted.

Sources

1. DrugPatentWatch.com – Jardiance (empagliflozin)